Invega Sustenna (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia and schizoaffective disorder. Invega Sustenna is given as an injection into your muscle by a ...

JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated ...

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.

A key rival could be Johnson & Johnson's recently-approved Invega Hafyera (paliperidone), which only needs to be administered twice-yearly, as well as J&J's older monthly and three-monthly ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Second place was Johnson & Johnson’s schizophrenia treatment Invega Sustenna/Invega Trinza (paliperidone), with a 6.8% increase in the list price – and 10.7% net – which added $203 million ...

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received Final Approval from the US Food & Drug ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.